The battle against dental caries has long been fought with conventional antimicrobial agents, with Chlorhexidine leading the charge. However, recent research has delved into the potential of probiotic metabolites as an alternative or adjunctive therapy in the quest for better oral health. In this editorial, we explore the emerging evidence surrounding the efficacy of probiotic metabolites compared to Chlorhexidine, specifically targetting local clinical isolates of Streptococcus mutans within dental plaque. Streptococcus mutans, a key player in the formation of dental plaque, has been a prime target for antimicrobial interventions due to its significant role in tooth decay. Chlorhexidine, a widely used antiseptic, has been a stalwart in dental care. However, its efficacy and potential side effects have prompted researchers to seek alternative approaches. Probiotic metabolites, byproducts of beneficial bacteria, have emerged as a promising avenue, with studies suggesting their ability to promote oral health by modulating the microbial balance.1 Recent studies have begun to unravel the intricate interactions between probiotic metabolites and Streptococcus mutans. These investigations have not only explored the direct antimicrobial effects but also the potential for probiotics to influence the overall microbial environment in the oral cavity. The comparison with Chlorhexidine, a gold standard in dental care, adds depth to our understanding of these alternative therapies.2 The evidence supporting the efficacy of probiotic metabolites in controlling Streptococcus mutans is not only encouraging but also challenges the status quo. A study by Gong SG et al. (2023) demonstrated that probiotic metabolites significantly reduced the growth of Streptococcus mutans in vitro, highlighting their potential as a potent antimicrobial agent.3 This finding is particularly promising given the increasing concerns about antibiotic resistance and the need for sustainable alternatives.
 Continued...
Read full abstract